Geopolitical rivalry forces sovereign regulators to streamline and repatriate drug manufacturing.
Intense competition with foreign adversaries compels national health authorities to build priority pathways that expedite early clinical phases and establish domestic production sites.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
The FDA is actively bypassing standard post-operational inspectorial delays to bring drug manufacturing back onto sovereign soil.
Securing sovereign medical pipelines requires overhauling clinical trial structures and accelerating the domestic regulatory gateway.
Geopolitical rivalry with China is forcing U.S. health authorities to implement structural reforms and streamlined pilot pathways to repatriate drug development pipelines.